These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23449029)

  • 1. Analysis of Epithelial Growth Factor-Receptor (EGFR) Phosphorylation in Uterine Smooth Muscle Tumors: Correlation to Mucin-1 and Galectin-3 Expression.
    Weissenbacher T; Vrekoussis T; Roeder D; Makrigiannakis A; Mayr D; Ditsch N; Friese K; Jeschke U; Dian D
    Int J Mol Sci; 2013 Feb; 14(3):4783-92. PubMed ID: 23449029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
    Poncelet C; Walker F; Madelenat P; Bringuier AF; Scoazec JY; Feldmann G; Darai E
    Hum Pathol; 2001 Nov; 32(11):1190-6. PubMed ID: 11727257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
    Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice.
    Moore AB; He H; Yoshida A; Rico PJ; Haseman JK; Dixon D
    Exp Toxicol Pathol; 2000 Jun; 52(3):195-200. PubMed ID: 10930119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173.
    Kong L; Deng Z; Shen H; Zhang Y
    Mol Cell Biochem; 2011 Feb; 348(1-2):11-9. PubMed ID: 21052789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
    Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
    Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs.
    Kim H; Kim Y; Goh H; Jeoung D
    Mol Cells; 2016 Mar; 39(3):229-41. PubMed ID: 26883907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients.
    Taberna M; Torres M; Alejo M; Mena M; Tous S; Marquez S; Pavón MA; León X; García J; Guix M; Hijano R; Bonfill T; Aguilà A; Lozano A; Mesía R; Alemany L; Bravo IG
    Front Oncol; 2018; 8():589. PubMed ID: 30619735
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
    Nishimura Y; Yoshioka K; Bereczky B; Itoh K
    Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.
    Magkou C; Nakopoulou L; Zoubouli C; Karali K; Theohari I; Bakarakos P; Giannopoulou I
    Breast Cancer Res; 2008; 10(3):R49. PubMed ID: 18522728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors.
    Schwarz G; Remmelink M; Decaestecker C; Gielen I; Budel V; Burchert M; Darro F; Danguy A; Gabius HJ; Salmon I; Kiss R
    Am J Clin Pathol; 1999 May; 111(5):623-31. PubMed ID: 10230352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of epidermal growth factor receptor and chromosome 7 polysomy in gastric adenocarcinoma.
    Zhang F; Tang JM; Wang L; Shen JY; Zheng L; Wu PP; Zhang M; Yan ZW
    J Dig Dis; 2012 Jul; 13(7):350-9. PubMed ID: 22713084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling.
    Samarakoon R; Higgins SP; Higgins CE; Higgins PJ
    J Mol Cell Cardiol; 2008 Mar; 44(3):527-38. PubMed ID: 18255094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different characteristics of mitochondrial microsatellite instability between uterine leiomyomas and leiomyosarcomas.
    Lee JH; Ryu TY; Cho CH; Kim DK
    Pathol Oncol Res; 2011 Jun; 17(2):201-5. PubMed ID: 20853077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
    Noordhuis MG; Eijsink JJ; Ten Hoor KA; Roossink F; Hollema H; Arts HJ; Pras E; Maduro JH; Reyners AK; de Bock GH; Wisman GB; Schuuring E; van der Zee AG
    Clin Cancer Res; 2009 Dec; 15(23):7389-97. PubMed ID: 19920104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
    Shanes ED; Friedman LA; Mills AM
    Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
    Poncelet C; Fauvet R; Feldmann G; Walker F; Madelenat P; Darai E
    J Surg Oncol; 2004 May; 86(2):84-90. PubMed ID: 15112250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.